Form 4: Sotera Health Director Ann Klee Receives Restricted Stock Unit Grant

Sotera Health Company's Director, Ann R. Klee, was granted 19,132 restricted stock units as part of her compensation, vesting over the next year.

Summary

• Ann R. Klee, a Director of Sotera Health Co (SHC), was granted 19,132 restricted stock units (RSUs) on May 22, 2025.
• These RSUs were granted under the Sotera Health Company 2020 Omnibus Incentive Plan.
• Each RSU represents the right to receive one share of Common Stock, subject to vesting conditions.
• The RSUs will vest in full on the earlier of the first anniversary of the grant date (May 22, 2026) or the date immediately prior to the Issuer's next regular annual shareholders meeting.
• Vesting is contingent upon Ms. Klee's continued service as a non-employee director.
• Following this transaction, Ms. Klee beneficially owns 125,956 securities, comprising 19,132 RSUs and 106,824 shares of Common Stock.

Sentiment

Score: 5

Explanation: The document reports a routine compensation event (RSU grant) to a director, which is a neutral event in terms of immediate financial performance or strategic shift. It reflects standard corporate governance and compensation practices.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value through equity compensation.
• It represents a standard compensation practice for non-employee directors, indicating continuity in corporate governance structure.

Negatives

• The transaction itself does not present any direct negative financial implications for the company, as it is a non-cash equity grant for compensation.

Future Outlook

The vesting of the granted restricted stock units is contingent on the director's continued service, aligning future compensation with ongoing contributions to the company.

Industry Context

The grant of restricted stock units to a non-employee director is a common practice across various industries, including healthcare and medical technology, to attract and retain qualified board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of director compensation is a widely adopted practice among publicly traded companies, including peers in the healthcare and sterilization services sector such as Steris plc (STE) or Cantel Medical Corp. (CMD, prior to acquisition).
• The vesting schedule, typically over one year or until the next annual meeting, is standard for non-employee director equity grants, reflecting a balance between immediate compensation and long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Ann R. Klee, a director, constitutes a transaction with a related party, which is a standard compensation arrangement disclosed in this filing.

Stakeholder Impact

• Shareholders: The grant of RSUs is a non-cash compensation expense that dilutes existing shares upon vesting but aims to align director incentives with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The RSUs are expected to vest on the earlier of May 22, 2026, or the date immediately prior to Sotera Health Company's next regular annual shareholders meeting, subject to continued service.

Key Dates

Keywords

Sotera Health, SHC, SEC Form 4, Restricted Stock Units, RSU grant, Director compensation, Insider transaction, Equity compensation, Corporate governance